Peter is currently VP Quality at Arsenal Biosciences, Inc., a clinical stage, programmable cell therapy company focused on solid tumor cell therapies to defeat cancer. Prior to joining ArsenalBio in 2021, Peter was at Novartis Pharmaceuticals, working with biologics and cell & gene therapy programs, including the Kymriah program from the initial collaboration with The University of Pennsylvania. Prior to the commercialization of Kymriah, Peter moved from a Quality function to an Operations function, ultimately having global responsibility for Novartis’ network of hospitals engaged with Kymriah and supplying autologous starting material for manufacturing. Originally trained as a microbiologist, Peter has also worked in contract microbiology testing at Perritt Laboratories, as well as various quality and compliance roles working with biologics, small molecules, and medical devices at Genentech, Anasiva, and Corthera during his career.